<DOC>
	<DOC>NCT01387321</DOC>
	<brief_summary>In this study, BYL719 will be administered to adult patients with advanced solid tumors whose disease has progressed despite standard therapy or for whom no standard therapy exists. The trial will investigate the safety and tolerability and determine the MTD of BYL719 in Japanese patients.</brief_summary>
	<brief_title>A Study of BYL719 in Adult Patients With Advanced Solid Malignancies</brief_title>
	<detailed_description />
	<criteria>Patients with histologicallyconfirmed, advanced unresectable solid tumors Availability of a representative formalin fixed paraffin embedded tumor tissue sample At least one measurable or nonmeasurable lesion Age ≥ 18 years Eastern Cooperative Oncology Group(ECOG) Performance Status ≤ 2 Good organ (hepatic, kidney, BM) function at screening/baseline visit Brain metastasis unless treated and free of signs/symptoms attributable to brain metastasis in the absence of corticosteroid therapy and antiepileptic therapy. Prior treatment with PI3K inhibitor Patient with peripheral neuropathy NCICTC Grade ≥ 2 Patient with diarrhea NCICTC Grade ≥ 2 Patient with acute or chronic pancreatitis Impaired cardiac function or clinically significant cardiac disease incl unstable angina pectoris ≤ 3 months prior to starting study drug and Acute Myocardial Infarction (AMI) ≤ 3 months prior to starting study drug Patients with clinically manifest diabetes mellitus, history of gestational diabetes mellitus or documented steroidinduced diabetes mellitus Women who are pregnant or breast feeding or adults of reproductive potential not employing an effective method of birth control Other protocoldefined inclusion/exclusion criteria may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Pi3K</keyword>
	<keyword>Advanced solid tumor</keyword>
</DOC>